Comparing of Efficacy and Safety Between Sintilimab Plus <scp>IBI305</scp> and <scp>PD</scp> ‐1 Inhibitor Plus <scp>TKIs</scp> in Combination of <scp>TACE</scp> for <scp>uHCC</scp>
The TSB and TTP regimens offer comparable efficacy and safety in uHCC, yet the TSB regimen appears to offer greater benefit in specific patient subgroups.
Authors
- C Y Liu
- Kaiwen Jiang
- Hesheng Lin
- Houxiang Ya
- Kai Wang
- Yi Zhou
- Jing Gu
- Shuqun Li
- Huixia Qin
Institutions
- Guilin Medical University (CN)
- Southern Medical University Shenzhen Hospital (CN)
Publication Details
- Journal
- Liver International
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1111/liv.70551
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 46.77